110.17
1.43 (1.32%)
| Previous Close | 108.74 |
| Open | 108.62 |
| Volume | 2,411,030 |
| Avg. Volume (3M) | 2,549,613 |
| Market Cap | 14,308,264,960 |
| Price / Sales | 15.92 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2026 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Guardant Health, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -1.20 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 155.00 (Leerink Partners, 40.69%) | Buy |
| Median | 120.00 (8.92%) | |
| Low | 105.00 (Evercore ISI Group, -4.69%) | Hold |
| Average | 124.23 (12.76%) | |
| Total | 12 Buy, 1 Hold | |
| Avg. Price @ Call | 101.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 09 Jan 2026 | 120.00 (8.92%) | Buy | 110.17 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (-4.69%) | Hold | 101.87 |
| 30 Oct 2025 | 90.00 (-18.31%) | Buy | 92.41 | |
| Guggenheim | 05 Jan 2026 | 115.00 (4.38%) | Buy | 101.87 |
| Canaccord Genuity | 22 Dec 2025 | 125.00 (13.46%) | Buy | 101.34 |
| 30 Oct 2025 | 100.00 (-9.23%) | Buy | 92.41 | |
| Mizuho | 17 Dec 2025 | 120.00 (8.92%) | Buy | 97.47 |
| Barclays | 15 Dec 2025 | 120.00 (8.92%) | Buy | 102.67 |
| 30 Oct 2025 | 85.00 (-22.85%) | Buy | 92.41 | |
| JP Morgan | 15 Dec 2025 | 120.00 (8.92%) | Buy | 102.67 |
| Leerink Partners | 15 Dec 2025 | 155.00 (40.69%) | Buy | 102.67 |
| Wells Fargo | 15 Dec 2025 | 120.00 (8.92%) | Buy | 102.67 |
| BTIG | 12 Dec 2025 | 140.00 (27.08%) | Buy | 102.07 |
| 30 Oct 2025 | 100.00 (-9.23%) | Buy | 92.41 | |
| Citigroup | 11 Dec 2025 | 135.00 (22.54%) | Buy | 101.38 |
| 30 Oct 2025 | 100.00 (-9.23%) | Buy | 92.41 | |
| Morgan Stanley | 02 Dec 2025 | 130.00 (18.00%) | Buy | 103.87 |
| UBS | 30 Oct 2025 | 110.00 (-0.15%) | Buy | 92.41 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | - | - | 0 | 0 |
| MONROE TERILYN J. | - | 111.98 | -8,808 | -986,320 |
| TARIQ MUSA | - | - | 0 | 0 |
| Aggregate Net Quantity | -8,808 | |||
| Aggregate Net Value ($) | -986,320 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 111.98 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | Director | 17 Jan 2026 | Option execute | 232 | - | - |
| MONROE TERILYN J. | Officer | 15 Jan 2026 | Disposed (-) | 8,808 | 111.98 | 986,320 |
| MONROE TERILYN J. | Officer | 15 Jan 2026 | Option execute | 17,379 | - | - |
| TARIQ MUSA | Director | 15 Jan 2026 | Option execute | 250 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |